$VTAE Wedbush Reiterates “Outperform” Rating for

New Post Public Reply Private Reply Replies (2) Message Board
fitzkarz
$VTAE

Wedbush Reiterates “Outperform” Rating for Vitae Pharmaceuticals Inc (VTAE)

Posted by paymon on Mar 7th, 2016 // No Comments

Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock. Wedbush’s price target suggests a potential upside of 326.44% from the stock’s current price.

VTAE has been the topic of a number of other research reports. Piper Jaffray reaffirmed a “buy” rating and set a $23.00 target price (up previously from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 10th. Wells Fargo started coverage on Vitae Pharmaceuticals in a report on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.

Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 4.69 on Thursday. Vitae Pharmaceuticals has a one year low of $4.15 and a one year high of $18.71. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $12.14. The firm’s market cap is $102.57 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s quarterly revenue was down 42.9% on a year-over-year basis. On average, analysts anticipate that Vitae Pharmaceuticals will post ($2.21) EPS for the current year.

A number of hedge funds have bought and sold shares of the stock. Ghost Tree Capital LLC boosted its stake in Vitae Pharmaceuticals by 10.0% in the fourth quarter. Ghost Tree Capital LLC now owns 275,000 shares of the company’s stock valued at $4,978,000 after buying an additional 25,000 shares in the last quarter. Boxer Capital LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $4,530,000. D. E. Shaw & Co. Inc. boosted its position in shares of Vitae Pharmaceuticals by 68.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,462 shares of the company’s stock valued at $3,683,000 after buying an additional 82,539 shares during the period. Millennium Management LLC boosted its position in shares of Vitae Pharmaceuticals by 15.2% in the fourth quarter. Millennium Management LLC now owns 873,436 shares of the company’s stock valued at $15,809,000 after buying an additional 114,981 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $2,096,000.

In related news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total value of $290,340.00. The disclosure for this sale can be found here.

Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 8

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 11

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 10

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
TA Services Strengthens U.S.-Mexico Freight Operations

Updated Category News Views 10

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 12

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
Northern Jet Names Veteran Matthew Harris as CEO

Updated Category News Views 24

Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...

Continue Reading
Epic Political Thriller Explores Humanity's Future

Updated Category News Views 5

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Continue Reading
JiMMYBAR! Expands Creatine Market with Target Launch

Updated Category News Views 13

JiMMYBAR! Breaks New Ground in Supplements You ever notice how some companies just know how to shake things up? Take JiMMYBAR!, for instance. The moment I read they’re making moves to get their Creatine + Protein bars into Target stores nationwide, starting October 4, I thought, “That’s one way to drag creatine out from the dusty tub and onto the shelves of...

Continue Reading
Karoo Health Leaps Forward with New CCO Breton

Updated Category News Views 10

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Continue Reading
Bob Evans' Protein Mac & Cheese: Practical Power Play

Updated Category News Views 18

Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...

Continue Reading

Top 5 Most Recently Viewed Articles

Elevate Your Knowledge on Elevance Health and Legal Matters

Updated Category News Views 164

Understanding the Legal Challenges Facing Elevance Health, Inc. Elevance Health, Inc. (NYSE: ELV) finds itself in the spotlight, facing a class action lawsuit that has significant implications for its shareholders. Legal firms are stepping in to represent investors who may have suffered losses due to the company's recent announcements regarding its Medicaid business. As...

Continue Reading
Revolutionizing Solar: Powur's Innovative Fulfillment Model

Updated Category News Views 256

Introducing Powur's Groundbreaking Fulfillment Model Powur PBC, a leader in the solar energy sector, is paving the way for innovation in solar project management. This new model is designed to enhance the delivery and installation of solar systems, ensuring accuracy and efficiency from the beginning of the project lifecycle. Understanding the COGS+ Model The newly...

Continue Reading
Revolutionizing Battery Technology: ProLogium and CEA Partnership

Updated Category News Views 174

Innovative Collaboration for Solid-State Battery Development ProLogium Technology, a leader in solid-state battery innovation, has recently joined forces with the CEA to unveil an ambitious initiative that focuses on the development of sophisticated solid-state battery modules. This collaboration centers around the concept of a "Design-for-Disassembly" structure that aims...

Continue Reading
Australia Employment Surpasses Expectations Despite Jobless Rate

Updated Category News Views 380

December Employment Numbers in Australia Surpass Projections In a noteworthy turn of events, Australian employment statistics for December have shown a remarkable rise, outstripping forecasts largely due to a considerable increase in part-time positions. While the jobless rate experienced a slight uptick, the overall data reflects a thriving labor market. Statistics...

Continue Reading
Vor Biopharma's Major Investment Targets Autoimmune Market Growth

Updated Category News Views 223

Strategic Moves in the Autoimmune Therapy Market Vor Biopharma Inc. (NASDAQ: VOR) is attracting attention with its recent strategic maneuver aimed at revitalizing the company and capitalizing on opportunities in the autoimmune market. The company has announced a notable licensing agreement that signifies its commitment to developing groundbreaking therapies. Licensing...

Continue Reading